Form 4: aTyr Pharma Inc. Executive Acquires Stock Options
SEC Form 4 Filing
Nancy Denyes, General Counsel of aTyr Pharma Inc., reports acquisition of stock options.
Summary
- Nancy Denyes, the General Counsel of aTyr Pharma Inc., filed a Form 4 on January 10, 2025, reporting a transaction.
- On January 8, 2025, Denyes acquired 275,000 employee stock options with an exercise price of $3.74.
- The options vest in 48 equal monthly installments starting February 8, 2025, and will be fully exercisable by January 8, 2029.
- The options are subject to accelerated vesting upon termination without cause upon a change of control of the issuer.
- Following the transaction, Denyes directly owns 275,000 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard executive compensation disclosure. The grant itself is a positive incentive, but the filing is routine.
Positives
- The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The vesting schedule indicates a long-term incentive plan for the executive, aligning her interests with the company's performance over the next four years.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and retain key personnel.
Comparison to Industry Standards
- Executive compensation packages, including stock options, are typically benchmarked against peer companies in the biotechnology sector.
- Companies like Amgen, Gilead Sciences, and Biogen often use similar stock option plans to incentivize their executives.
- The vesting schedule and exercise price are usually determined based on industry standards and the executive's role and responsibilities.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the executive to drive company growth.
- Employees may see this as a sign of stability and investment in the leadership team.
Key Dates
| Date | Description |
|---|---|
| 01/08/2025 | Date of the stock option grant. |
| 02/08/2025 | First vesting date of the stock options. |
| 01/08/2029 | Date when the stock options are fully vested. |
| 01/08/2035 | Expiration date of the stock options. |
| 01/10/2025 | Date the Form 4 was filed. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.